grastim Peripheral blood progenitor cells (PBPCs) are the preferred source of stem cells in autologous transplantation. They can be obtained after single-agent or combination chemotherapy followed by growth factors, or with growth factors alone. [1] [2] [3] However, not all patients can be successfully mobilised using such protocols. Some studies have shown an increase in yield of CD34 þ cells using submyeloablative chemotherapy in combination with growth factors. 2, [4] [5] [6] High-dose cyclophosphamide is a widely used agent; however, this is associated with significant morbidity and increased costs due to hospital admissions.
Cyclophosphamide has been used in a wide range of doses between 1.5 and 7 g/m 2 in various studies. [6] [7] [8] [9] [10] Growth factor alone is used in dosages ranging from 3 to 32 mg/kg/ day. 6, 11, 12 The dose-response curve flattens at about 10 mg/ kg/day and this is the most commonly used and the recommended dose. 6 Some studies have demonstrated the yield of CD34 þ cells to be superior to in-patients who have been treated with chemotherapy and growth factors rather than growth factor alone. 6, 9, 10 There has been only one previous randomised study comparing cyclophosphamide and G-CSF with G-CSF alone. 1 In this trial, we investigated the yield of CD34 þ cells following intermediate dose of cyclophosphamide followed by lenograstim (Cyclo-G-CSF group) vs lenograstim alone at 10 mg/kg/day (G-CSF group). We also compared the impact of the two regimens on morbidity, time spent in hospital, number of apheresis procedures and engraftment.
Patients and methods
Between November 1998 and November 2002, 79 patients with various haematological malignancies were enrolled into a trial comparing intermediate-dose cyclophosphamide þ G-CSF vs G-CSF alone. Patients gave written informed consent and the protocol was approved by the institutional ethics committee.
Patients were eligible for this study if aged over 17 years, gave written informed consent, and were diagnosed to have either Hodgkin's disease (HD), non-Hodgkin's lymphoma (NHL), myeloma (MM) or chronic lymphocytic leukaemia (CLL), had no serious underlying medical condition and no serious psychiatric problems. Patients were excluded if unable or unwilling to give informed consent, were pregnant or had known hypersensitivity to G-CSF.
Study end points
The primary end point of this study was to compare the two progenitor cell mobilisation schedules with regard to successful mobilisation (X2.0 Â 10 6 /kg CD34 þ cells) and number of apheresis procedures required to collect adequate stem cells. The secondary end points were to compare the quality of life and time spent in or visiting the hospital during the procedures. In addition, the times for neutrophil (40.5 Â 10 9 /l) and platelet (420 Â 10 9 /l) engraftment were also compared between the patients in the two groups transplanted with stem cells obtained from a single mobilisation attempt.
Study design
This was a randomised open-label study. Patients were randomised to receive either G-CSF alone or cyclophosphamide and G-CSF, stratified by diagnosis (NHL, HD, CLL and myeloma) and stage (early or advanced). Early disease was defined as patients needing o3 chemotherapeutic regimens prior to stem cell collection and late disease as patients needing X3 chemotherapeutic regimens.
Mobilisation regimens and PBSC collection. In all, 79 patients were randomised to receive one of the two regimens. A total of 40 patients were randomised to receive G-CSF alone at 10 mg/kg/day on days 1-5 or until PBPC harvest was completed, which was initiated on day 5. Altogether, 39 patients were randomised to receive cyclophosphamide 2 g/m 2 on day 1 and received G-CSF 5 mg/kg/day from day 5 until harvest. Patients also received mesna 1 g/m 2 before cyclophosphamide, followed by two further doses at 4 and 8 h after cyclophosphamide. PBPC harvest was performed between days 11 and 13. Apheresis was performed when peripheral CD34 count reached 20 Â 10 6 /l or WBC X4 Â 10 9 /l in both groups. The intention was that all the patients would be managed as out-patients.
The end point of stem cell apheresis in each arm was the collection of total CD34 þ cells 42 Â 10 6 /kg or three apheresis procedures. Mobilisation failure was defined as failure to collect CD34 þ cells of 2.0 Â 10 6 /kg after three apheresis procedures. Patients who failed to mobilise adequate PBPC with one regimen were crossed over to the other arm.
Toxicity grading between the two regimens. All patients were requested to complete a diary regarding the treatment received, time spent in hospital each day as well as symptoms of nausea, vomiting and bone pain. The symptoms were scored 0-5 (0 ¼ none and 5 ¼ severe).
Statistical methods. Parameters compared between the two arms were the following: number of patients successfully mobilised; number of apheresis procedures required; total number of CD34 þ cells collected per kg body weight; treatment-related toxicities; total duration of time spent in or attending the hospital. Pearson's w 2 and Fisher's exact test were used to test for associations between categorical variables. The Mantel Haenszel w 2 test for linear association was used to compare ordinal data such as mobilising efficiency and toxicities such as nausea, vomiting and bone pain, and the Wilcoxon test to compare the number of apheresis procedures and time spent in hospital in each arm. The cumulative probability of neutrophil and platelet engraftments was estimated by the Kaplan-Meier method and compared between the two arms using the log rank test.
Results

Patient characteristics
In all, 40 patients were randomised to receive G-CSF alone and 39 patients to receive cyclo-G-CSF. Patient characteristics are shown in Table 1 . There was no difference in the age, underlying disease or stage of disease between the groups. The mean number of prior regimens in the G-CSF alone arm was 1.42 and in the cyclo G-CSF arm was 1.55. Altogether, 84.3 and 84.7% had bone-marrow involvement in the G-CSF and cyclo GCSF groups, respectively. Successful PBPC mobilization. Successful mobilisation was achieved in 22/39 patients (54.6%, 95% CI 40-72) in the cyclo-G-CSF arm and 28/40 patients (70%, 95% CI 53-83) in the G-CSF groups, respectively (P ¼ 0.21, Figure 1 ). The median number of CD34 þ cells collected was 2.3 Â 10 6 /kg (range 0.1-5.8) in the G-CSF arm and 2.2 Â 10 6 /kg (range 0-10) in the cyclo-G-CSF arm. There was no difference in the number of apheresis procedures required between the two groups and the median was 2.0 for both regimens. The only variable associated with the failure of mobilisation was diagnosis of CLL. Failure to mobilise progenitor cells was significantly higher in the CLL subgroup when compared with the non-CLL subgroup (P ¼ 0.0003, Figure 2 ). There were 22 patients in the CLL subgroup and only 7/22 (31.9%) had successful mobilisation. There was no difference in the mobilisation potential between the two regimens (3/10 for cyclo-G-CSF and 4/12 for G-CSF, P ¼ 0.87). All patients in the CLL subgroup had early disease and had previously received fludarabine. A high proportion 15/22 (68.2%) of CLL patients failed to mobilise. Failure to mobilise was seen in 10/57 (17.5%) non-CLL patients (MM, NHL, HD). The overall failure rate in this study was 25/79 (31.6%).
After failure of mobilisation, 19 patients (n ¼ 19) were crossed to the alternative regimen, out of which only 5/19 patients could be successfully mobilised. Five of the 11 patients crossing over to the G-CSF arm mobilised successfully, compared to none of the eight patients crossing over to the cyclo-G-CSF arm (P ¼ 0.03). Out of the 15 patients, 10 patients with CLL crossed over to the other arm. None of the six patients crossing to the cyclo-G-CSF arm mobilised successfully, with CD34 þ cells above 1 Â 10 6 /kg achieved in one patient only. Two of the four patients crossing over to the G-CSF arm mobilised above 6 /kg CD34 þ cells, with another patient mobilising 1.7 Â 10 6 /kg CD34 þ cells.
Total time spent in the hospital as day case and hospital admissions. The time spent in the hospital as a day case was significantly higher in the cyclo-G-CSF group. The median duration of attendance in the cyclo-G-CSF group was 28.5 vs 20.9 h in the G-CSF group (P ¼ 0.01). Four patients in the cyclo-G-CSF group (4/39) were hospitalised due to sepsis and none in the G-CSF alone group.
Toxicities of mobilising regimens. The toxicity data are restricted to 28 patients in cyclo-G-CSF group and 22 patients in the G-CSF group, for whom the returned diaries could be analysed. Although both regimens were fairly well tolerated, nausea and vomiting were significantly higher in the cyclo-G-CSF group.
In all, 22 of 28 (79%) vs 8/22 (36%) had nausea (P ¼ 0.0004) and 16/28 (57%) vs 2/22 (9.1%) had vomiting (P ¼ 0.002) in the cyclo-G-CSF and G-CSF groups, respectively. The median durations of nausea and vomiting were 3 days and 1 day for the cyclo-G-CSF group vs 0.5 day and 0.14 day for the G-CSF group (P ¼ 0.0008). Severe nausea and vomiting were observed in the cyclo-G-CSF group alone. There was no difference in bone pain between the two groups, with 21/28 (75%) vs 18/22 (82%) in cyclo-G-CSF and G-CSF groups respectively (P ¼ 0.26).
Engraftment
In all, 50 patients underwent successful mobilisation, 22 in the cyclo-G-CSF group and 28 in the G-CSF arm. All transplanted patients had durable engraftment. Neutrophil engraftment occurred at a median of 14 days for both groups (range 12-21 days for the cyclo-G-CSF group and 11-39 days for the G-CSF group, P ¼ 0.47). Platelet engraftment was achieved at a median of 14 days (range 9-36) for the cyclo-G-SCF group and 15 days (range 11-121) for the G-CSF group (P ¼ 0.12).
Discussion
PBPC mobilisation can be achieved using various combinations of chemotherapy or single agents such as cyclophosphamide in dosages varying from 1.5 to 7 g/m 2 , followed by growth factors. [6] [7] [8] [9] [10] Some studies have shown a higher yield of CD34 þ cells following chemotherapy and growth factors than growth factors alone. 2, 6 Although increasing the cyclophosphamide dose in combination with growth factor produces increased numbers of CD34 þ cells, this is associated with increased toxicity and morbidity. To overcome this, there is now a trend towards using intermediate-dose cyclophosphamide (2 g/m 2 ) combined with growth factor. This may permit the mobilisation procedure to be conducted entirely as an out-patient.
However, a proportion of patients have resistant or active relapse at the time of transplant. Cyclophosphamide alone has limited anti-lymphoma activity. Under these circumstances, combination chemotherapeutic agents are required both to debulk the disease and to mobilise stem cells. Mini-BEAM or dexa-BEAM regimens are myelotoxic and have limited use in this context. 3, 5 Successful mobilisation can be achieved by IVE (ifosphamide, etoposide, epirubicin) plus G-CSF. 13, 14 IVE plus G-CSF is shown to be superior to cyclophosphamide 3 g/m 2 plus G-CSF in mobilising progenitor cells in resistant or relapsed lymphoma.
14 ESHAP (etoposide, cisplatin, cytarabine, methyl prednisolone) plus G-CSF is another widely used mobilisation regimen, which is found to be highly effective, well tolerated and less toxic than DHAP. 3 However, combination chemotherapy has the disadvantage of excessive morbidity, in-patient hospital stay, and increased hospital costs, and is not suitable for all patients.
Our study confirms that G-CSF alone at 10 mg/kg/day is as efficient at mobilising progenitor cells as a combination of cyclophosphamide (2 ) and G-CSF 5 mg/kg/day was our unit's preferred mobilisation schedule prior to this study. The doses of G-CSF are not directly comparable, and therefore a higher success rate may be seen by using the combination cyclophosphamide (2 g/m 2 ) and G-CSF 10 mg/kg/day. This would increase the cost of mobilisation both in terms of discomfort to the patient (double the volume of injection) and financially. G-CSF alone results in a significant reduction in nausea, vomiting and time spent in hospital. Four patients (10.2%) in the cyclo-G-CSF group were hospitalised due to neutropenic sepsis. In view of the small numbers, it is difficult to draw firm conclusions; however, in the G-CSF group, no patients were hospitalised and morbidity and hospital costs were reduced. There was no difference in bone pain between the groups. Although the drug costs in the G-CSF subgroup are higher, there was significant reduction in morbidity, reduced time spent in hospital and improved quality of life.
One study has analysed the factors associated with poor mobilisation with G-CSF alone in lymphoid malignancies. 15 A diagnosis of CLL among others and previous fludarabine therapy were found to be predictive of poor mobilisation. The overall failure rate (o2.0 Â 10 6 /kg CD34 þ cells) is high. We believe the overall results have been skewed to failure by a high proportion of CLL patients. Our unit has an active clinical research effort towards CLL and we participated in the UK MRC CLL pilot study of PBSC autologous transplants. Patients with CLL, particularly with previous exposure to fludarabine, seem to be a subgroup, which poorly mobilises with either regimen. The negative impact of fludarabine therapy on stem cell mobilisation has been reported. 15, 16 Fludarabine may be more important in negatively predicting the success of mobilising regimens. Thus, in this group of patients, it might be worth considering other novel mobilisation protocols. None of the other subgroups in our study had been treated with fludarabine and thus the relative contribution of fludarabine as compared to the underlying disease could not be established.
The previous randomised study employed G-CSF at 10 mg/kg/day in both arms and used a higher dose of cyclophosphamide (5 g/m 2 ) in the cyclo-G-CSF arm. 1 The median number of CD34 þ cells collected by a combination of cyclophosphamide and G-CSF was higher than that obtained with G-CSF alone. This trial was conducted on a smaller cohort with 21 patients in each group and mobilisation-related quality of life assessments were not carried out. 1 However, the engraftment potential did not differ between the two groups despite fewer CD34 þ cells collected in the G-CSF arm. We confirm that there was no difference in the engraftment kinetics with the use of stem cells obtained by either mobilisation procedure. Even though the absolute number of CD34 þ cells has tended to correlate with the speed of engraftment, there is possibly a threshold beyond which engraftment is not influenced. 17 Some studies have demonstrated that G-CSF when used alone might provide superior migration and homing potential for mobilised CD34 þ cells.
